GLP-1 Market
LLY $1364.73 ▼ -3.8% NVO $40.30 ▼ -4.5% PFE $29.88 ▼ -3.0% VKTX $25.79 ▼ -7.8% KLRA $12.17 ▼ -4.9% GPCR $19.08 ▼ -6.3% RHHBY $59.45 ▼ -2.4%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Measles-Rubella vaccine

Company
Nicole Stoffel
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Nov 6, 2026

Find a Clinical Trial Near Me

See recruiting studies for Measles-Rubella vaccine and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT06816524

    The Effects of Iron Treatment on Vaccine Immunogenicity in Kenyan Infants With Iron Deficiency

    Not yet reported Nicole Stoffel 324 participants Est. completion 2028-04-30 1 site
    Other conditions: Iron Deficiencies
    View official trial listing →
  • Completed NCT NCT01700621

    Coadministration of Measles-rubella and Rotavirus Vaccines

    Not yet reported PATH 482 participants Est. completion 2013-09 1 site Stand-alone
    Other conditions: Measles Antibody Seroconversion, Rubella Antibody Seroconversion, Rotavirus Geometric Mean Titer (GMT), Rotavirus Immunoglobulin A (IgA) Seropositivity
    View official trial listing →
  • Status unknown NCT NCT02153866

    The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR Vaccine

    Not yet reported Sichuan Center for Disease Control and Prevention 2800 participants Est. completion 2014-08 Stand-alone
    Other conditions: Rotavirus
    View official trial listing →
  • Completed NCT NCT03071575

    Measles-Rubella Vaccine Immunogenicity at 6 and 9 Months of Age

    Not yet reported Centers for Disease Control and Prevention 637 participants Est. completion 2018-03-18 1 site Stand-alone
    Other conditions: Measles, Rubella, Rubella Syndrome, Congenital
    View official trial listing →
  • Completed NCT NCT03680417

    Reactogenicity and Protectivity Following Measles- Rubella (MR) Routine Immunization in Indonesian Infants and Children

    Not yet reported PT Bio Farma 590 participants Est. completion 2018-08-01 1 site
    Other conditions: Safety Issues, Immunogenicity
    View official trial listing →
  • Completed NCT NCT04183114

    Immunogenicity & Safety of Bio Farma's Measles-Rubella (MR) Vaccine in Indonesian Infants (Bridging Study)

    Not yet reported, Not yet reported PT Bio Farma 540 participants Est. completion 2019-11-11 1 site Stand-alone
    Other conditions: Congenital Rubella Infection, Measles
    View official trial listing →
  • Completed NCT NCT04394689

    Measles and Rubella Vaccine Microneedle Patch Phase 1-2 Age De-escalation Trial

    Not yet reported, Not yet reported Micron Biomedical, Inc 281 participants Est. completion 2022-12-31 1 site
    Other conditions: Measles, Rubella, Vaccination, Healthy
    View official trial listing →
  • Completed NCT NCT05073003

    A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants

    Not yet reported, Not yet reported GlaxoSmithKline 551 participants Est. completion 2025-06-24 2 sites Stand-alone
    Other conditions: Diarrhoea
    View official trial listing →
  • Status unknown NCT NCT06667206

    Earlier Prime-BOOST Schedule to Improve MEasles Protection in High Burden Settings

    Not yet reported University of Oxford 450 participants Est. completion 2026-05-10 1 site Stand-alone
    Other conditions: Measles
    View official trial listing →
  • Not yet recruiting NCT NCT06815835

    Non-interference Study of MR and Yellow Fever Vaccines Among Bangladeshi Infants Aged 9-12 Months

    Not yet reported International Centre for Diarrhoeal Disease Research, Bangladesh 1530 participants Est. completion 2026-03-31 1 site Stand-alone
    Other conditions: Measles, Rubella, Yellow Fever
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.